Table IV.

Characteristics of PWH with likely indications for statin use, by race/ethnicity

	Black (n = 508)	Hispanic (n = 143)	White (n = 610)	P
Age, y (mean)	54.0 (53.2–54.8)	52.2 (50.7–53.8)	55.9 (55.2–56.7)
Sex, n male (%)	385 (75.8%)	113 (79.0%)	561 (92.0%)	<.001
HTN diagnosis, n (%)	412 (81.1%)	96 (67.1%)	404 (66.2%)	<.001
DM diagnosis, n (%)	185 (36.4%)	58 (40.6%)	137 (22.5%)	<.001
CHD diagnosis, n (%)	306 (60.2%)	65 (45.5%)	237 (38.9%)	<.001
Nadir CD4 (95% CI), cells/mm3	199.9 (182.9–216.8)	261.5 (226.2–296.8)	272.0 (255.9–288.1)	<.001
Log10 of peak HIV viral load	9.9 (9.6–10.2)	9.1 (8.5–9.7)	8.6 (8.3–8.9)	<.001
ART use, n (%)	444 (87.4%)	131 (91.6%)	583 (95.6%)	<.001
Protease inhibitor–based ART, n (%)	298 (58.7%)	86 (60.14%)	364 (59.7%)	.92
Taking statin, n (%)	200 (39.4%)	66 (45.8%)	340 (55.7%)	<.001